Pacritinib for Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
This study is testing pacritinib in people with T-cell lymphoproliferative neoplasms (cancers of certain white blood cells) that have returned or not responded to previous treatments. The main goal is to see how many people respond to pacritinib. You would take pacritinib 200mg twice daily. The study is open to adults aged 18 and older who meet specific health criteria, including an ECOG performance status of 2 or less (a measure of how well you can perform daily activities). The study plans to enroll 100 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 100 participants into one of four groups based on their specific type of T-cell lymphoma.
- What's involved
- You will receive pacritinib 200mg orally twice daily until your doctor determines treatment should stop.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main outcome (overall response rate) will be measured for up to 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
At a glance
Conditions
NCT04858256
Where you'd take part
This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
City of Hope
Duarte, Californiastudy coordinator listed
Recruiting
Duke Cancer Institute
Durham, North Carolinastudy coordinator listed
Recruiting
Moffitt Cancer Center
Tampa, Floridastudy coordinator listed
Not yet recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohiostudy coordinator listed
Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michiganstudy coordinator listed
Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvaniastudy coordinator listed
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Ryan Wilcox, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Michigan Rogel Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Overall response rate (ORR)Up to 2 years
ORR will be estimated for each disease-specific cohort of patients. Overall response is defined as best disease response recorded from first day of treatment until disease progression or treatment discontinuation. Response in PTCL patients is assessed by PET/CT scan using the Response Evaluation Criteria in Lymphoma (RECIL) criteria. Response in CTCL patients is assessed using the modified Severity Weighted Assessment Tool (mSWAT). Results will be stratified by type: complete response \[CR\], partial response \[PR\], minor response \[MR; a provisional category in RECIL only\], stable disease \[SD\], progressive disease \[PD\]; and by cohort.